Incidence of GVHD and survival based on GVHD grade
Out of 183 evaluable patients, 110
(60.1%) did not have any evidence of aGVHD, 33 (18%) had aGVHD grade
I, 23 (12.6%) grade II, 7 (3.8%) grade III, and 10 (5.5%) grade IV.
One hundred forty-four patients (78.7%) did not have cGVHD, 16 (8.7%)
had chronic limited, and 23 (12.6%) had chronic extensive GVHD. Table 2
describes the incidence of GVHD by donor relation, stem cell source and
HLA-match. Patients receiving unrelated mismatched donor BM, PB, or
mismatched UCB had the highest incidence of aGVHD (68.7% and 63.2%,
respectively). The incidence of aGVHD in haploidentical and MRD
recipients was 36.4% and 29.6%, respectively. However, there was no
aGVHD grade III/IV among haploidentical HCT recipients. FIGURE 1 depicts
overall survival by acute GVHD grade and FIGURE 2 depicts overall
survival by cGVHD grade. Patients without aGVHD, aGVHD grade I/II, and
aGVHD grade III/IV had 3-year survival of 90.1% [95%CI 84-96],
98.1% [95%CI 95-100], and 52.9% [95%CI 34-83], respectively.
The difference in survival among the 3 groups was significant (log rank
p<0.0001). Patients without cGVHD and those with limited and
extensive cGVHD had 3-year survival rates of 88.9% [95%CI 84-94],
91.7% [95%CI 77-100], and 84.8% [95%CI 70-100],
respectively. Neither limited nor extensive cGVHD significantly affected
3-year survival rates (log rank p=0.3).